Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.
Division of Nursing Research and Education, Beckman Research Institute, City of Hope, Duarte, California, USA.
J Palliat Med. 2022 May;25(5):720-727. doi: 10.1089/jpm.2021.0187. Epub 2021 Oct 26.
Pancreatic cancer patients often present with complications, which can impact treatment tolerance. Thus, symptom management is a vital component of treatment in addition to traditional chemotherapeutics. Concurrent palliative care with an emphasis on aggressive symptom management may sustain both clinical and patient-centered outcomes during treatment. The purpose of this article is to explore the impact of a concurrent palliative care intervention in patients with pancreatic cancer treated on phase I clinical trials. This is a secondary analysis of a National Cancer Institute (NCI)-funded randomized trial of an advanced practice nurse driven palliative care intervention for solid tumor patients treated on phase I clinical trials. Only pancreatic cancer patients were included in the analysis. Patients received two educational sessions around the quality of life (QOL) domains and completed the Functional Assessment of Cancer Therapy-General (FACT-G), patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE), and the psychological distress thermometer at baseline, 4 and 12 weeks. Mixed model with repeated measures analysis was used to explore outcomes by study arm. Of the 479 patients accrued to the study, 42 were diagnosed with pancreatic cancer (26 intervention, 16 usual care). A trend toward improvement in the physical, social, emotional, and functional FACT-G QOL subscales and psychological distress (baseline to 12 weeks) were observed for the intervention arm. Patients reported moderate severity in psychological and physical stress. In this secondary analysis, a nurse-led palliative care intervention may improve the QOL and psychological distress of pancreatic cancer patients. A phase III trial focused on patients with pancreatic cancer is needed to determine the effectiveness of the intervention.
胰腺癌患者常伴有并发症,这可能影响治疗的耐受性。因此,除了传统的化疗之外,症状管理也是治疗的重要组成部分。在治疗过程中同时进行姑息治疗,重点是积极的症状管理,可以维持临床和以患者为中心的治疗结果。本文旨在探讨在接受 I 期临床试验治疗的胰腺癌患者中同时进行姑息治疗干预的影响。 这是一项由美国国家癌症研究所 (NCI) 资助的随机试验的二次分析,该试验评估了由高级实践护士驱动的姑息治疗干预对接受 I 期临床试验治疗的实体瘤患者的疗效。只有胰腺癌患者被纳入分析。患者接受了两次关于生活质量 (QOL) 领域的教育课程,并在基线、4 周和 12 周时完成了癌症治疗功能评估-一般 (FACT-G)、患者报告的常见不良事件术语标准 (PRO-CTCAE) 和心理困扰温度计。使用混合模型重复测量分析来探索研究臂的结果。 在纳入的 479 名患者中,有 42 名被诊断为胰腺癌(26 名干预组,16 名常规护理组)。干预组的身体、社会、情感和功能 FACT-G QOL 子量表以及心理困扰(基线至 12 周)均呈改善趋势。患者报告心理和身体压力处于中度严重程度。 在这项二次分析中,护士主导的姑息治疗干预可能会改善胰腺癌患者的生活质量和心理困扰。需要一项针对胰腺癌患者的 III 期试验来确定该干预措施的有效性。